Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2014 · 10-Q
Revenue—
Net Income$3.52M$3.52MN/M vs Q2 2013 EPS Diluted$0.10$0.10N/M vs Q2 2013 Operating Income-$4,424,616N/M Operating Cash Flowderived-$2,571,124—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,697,864— ended Jun 30, 2014 · filed Aug 12, 2014 · 43 d after period end